CTLA4 and neoplasm: A comparable correlation between low baseline intestinal inflammation and disease control was demonstrated in patients with hepatocellular carcinoma (HCC) treated with the CTLA-4 and/or PD-L1 inhibitors, suggesting that durable inflammation in the gut may lead to the exhaustion of the immune system and, in consequence, facilitate tumor immune escape [40].